Vaginal health, endometrial thickness and changes in bone markers in postmenopausal women after 6 months of treatment with ospemifene in real clinical practice

• Published in: Gynecological endocrinology 2022-01, Vol.38 (1), p.78-82
• Main Authors: Pingarrón, Carmen, Lafuente, Pilar, Poyo Torcal, Silvia, López Verdú, Helena, Martínez García, María Sol, Palacios, Santiago
• Format: Article
• Language: English
• Subjects: Biomarkers - blood; Bone and Bones - drug effects; Bone and Bones - physiology; bone mineral density; Bone Resorption; bone resorption marker; endometrial thickness; Endometrium - anatomy & histology; Endometrium - drug effects; Female; Humans; Ospemifene; Postmenopause - drug effects; Postmenopause - physiology; Prospective Studies; Tamoxifen - administration & dosage; Tamoxifen - analogs & derivatives; Ultrasonography; Vagina - drug effects; Vagina - physiology; vulvovaginal atrophy
• ISSN: 0951-3590; 1473-0766
• DOI: 10.1080/09513590.2021.1970740

To assess vaginal health, endometrial thickness, and changes in bone markers in postmenopausal women with vulvovaginal atrophy (VVA) treated with 60 mg/day of ospemifene under routine clinical practice. The AYSEX study is a Spanish observational and prospective study performed in one center in which 5 gynecologists recruited postmenopausal women with VVA in routine clinical practice treated continuously with ospemifene 60 mg/day for 12 months as an appropriate therapeutic option. This article refers to the 3- and 6-months analysis. Vaginal health was assessed by pH and using Vaginal Health Index (VHI) at baseline and 3 months later. Endometrial thickness, measured by vaginal ultrasonography, and bone resorption marker (CTx) were assessed at baseline and 6 months later. A total of 100 postmenopausal women cytologically and clinically diagnosed with VVA were included in the study. After 3 months of treatment with ospemifene, pH improved from 6.1 to 4.5 (p